Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients.

摘要: Abstract:  Transplant patients are at increased risk of developing dyslipidemia, which contributes to coronary artery disease and cardiovascular events. The purpose this study was explore documented adverse effects liver transplant recipients receiving lipid-lowering therapies. Methods:  A retrospective chart review 69 conducted evaluate the incidence effects, especially rhabdomyolysis function abnormalities, in treated with a lipid lowering agent (LLA). Data were collected from time initiation LLA 12 months later, looking type, dose, duration LLA, concurrent cytochrome P450 inhibitors, immunosuppression used, laboratory parameters. Results:  For HMG-CoA reductase inhibitor therapy, simvistatin used five (7.8%) patients, pravastatin 40 (62.5%), fluvastatin one (1.6%), atorvastatin (7.8%), lovastatin three (4.7%). Gemfibrozil, fibric acid derivative, employed as monotherapy 10 (15.6%) patients. There who received combination therapy four (80%) gemfibrozil + pravastatin, (20%) gemfibrozil + simvastatin. Six studied had (7.2%) myalgia (1.4%) myopathy. either or these on cyclosporin, patient myopathy cyclosporin + diltiazem both inhibitors. One out 23 non-immunosuppressant developed effects. No significant elevation alanine aminotransferase, aspartate alkaline phosphatase noted any patient. Conclusions:  Overall, there general tolerability low events, no severe complications, alterations tests population use LLA.